The stock price of Matinas Biopharma Holdings Inc (AMEX: MTNB) has jumped by 12.61 compared to previous close of 0.60. Despite this, the company has seen a gain of 11.67% in its stock price over the last five trading days. globenewswire.com reported 2025-03-11 that BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the “Effective Date”).
Is It Worth Investing in Matinas Biopharma Holdings Inc (AMEX: MTNB) Right Now?
MTNB has 36-month beta value of 1.17. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for MTNB is 4.56M, and currently, short sellers hold a 4.26% ratio of that float. The average trading volume of MTNB on April 28, 2025 was 128.60K shares.
MTNB’s Market Performance
MTNB’s stock has seen a 11.67% increase for the week, with a 17.38% rise in the past month and a 9.84% gain in the past quarter. The volatility ratio for the week is 8.61%, and the volatility levels for the past 30 days are at 9.43% for Matinas Biopharma Holdings Inc The simple moving average for the past 20 days is 19.29% for MTNB’s stock, with a -73.59% simple moving average for the past 200 days.
Analysts’ Opinion of MTNB
Piper Sandler gave a rating of “Overweight” to MTNB, setting the target price at $3 in the report published on January 27th of the previous year.
MTNB Trading at 18.31% from the 50-Day Moving Average
After a stumble in the market that brought MTNB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.11% of loss for the given period.
Volatility was left at 9.43%, however, over the last 30 days, the volatility rate increased by 8.61%, as shares surge +18.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.33% upper at present.
During the last 5 trading sessions, MTNB rose by +11.67%, which changed the moving average for the period of 200-days by -91.64% in comparison to the 20-day moving average, which settled at $0.5617. In addition, Matinas Biopharma Holdings Inc saw 31.37% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for MTNB
The total capital return value is set at -2.47. Equity return is now at value -180.73, with -62.01 for asset returns.
Based on Matinas Biopharma Holdings Inc (MTNB), the company’s capital structure generated 0.28 points at debt to capital in total, while cash flow to debt ratio is standing at -5.49.
Currently, EBITDA for the company is -24.59 million with net debt to EBITDA at 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.01.
Conclusion
To put it simply, Matinas Biopharma Holdings Inc (MTNB) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
